

## Lumito and Concept Life Sciences join forces to advance tissue analysis in drug discovery

**We are excited to announce a collaboration between Lumito and Concept Life Sciences, a CRO (contract research organisation) based in UK, to enhance tissue analysis in drug discovery and development. This joint project will focus on evaluating and optimising Lumito's innovative product Scizys, within Concept Life Sciences' cutting-edge research service.**

This collaboration is more than just an evaluation, it's a pathway for Lumito to expand the company market presence and visibility outside Sweden. The success of this project could serve as a launchpad for wider adoption of Lumito's solution and position Lumito as an important player in tissue analysis, as well as paving the road for further commercialisation.

The project will be based on Lumito's "scan-as-a-service" concept, where Concept Life Sciences will utilise Scizys Erbium kit to develop automated staining protocols before sending the samples to Lumito for high resolution scanning. The images and data from the scanning are then transferred back to Concept Life Sciences for analysis and evaluation.

"We are really excited about this collaboration with the skilled and experienced team from Concept Life Sciences. By working together, we aim to advance and enhance tissue analysis to meet the needs of Concept Life Science and their customers, adding value for both companies" says Sanna Wallenborg, CEO at Lumito.

"Lumito is generating some really exciting data, showcasing both the sensitivity and range of detection of their assay. This could be of real benefit to the spatial biology sector where accurate and measurable detection of protein can be difficult. We are really excited to be part of the development of such a technology" says Chris Mills, Senior Scientist, Concept Life Sciences.

"Our collaborative approach drives breakthroughs in spatial biology and biomarker discovery, leveraging high-quality data to advance target validation, tissue analysis, and precision medicine. At Concept Life Sciences, we partner with innovators like Lumito, using cutting-edge imaging and spatial profiling to unlock deeper biological insights. By integrating advanced spatial techniques, we accelerate biomarker discovery and therapeutic development, bringing precision therapies to patients faster" says Hayley Gooding, Biology Services Director, Concept Life Sciences.

### For further information, please contact:

---

Sanna Wallenborg, CEO Lumito  
E-mail: [sw@lumito.se](mailto:sw@lumito.se)  
Ph: +4670-870 01 68

**About Lumito**

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. [www.lumito.se/en/](http://www.lumito.se/en/)

**About Concept Life Sciences**

Concept Life Sciences is an innovative Contract Research Organization (CRO) dedicated to accelerating drug discovery and development through cutting-edge scientific expertise and state-of-the-art technologies. With a multidisciplinary team specializing in biology, chemistry, ADME/DMPK, and bioanalytics, they provide tailored solutions to pharmaceutical and biotech companies, helping them navigate the complexities of drug discovery from concept to clinic.

**Attachments**

[Lumito and Concept Life Sciences join forces to advance tissue analysis in drug discovery](#)